{"title":"大肠癌肝转移中的核酸梭菌、免疫反应和转移器官多样性","authors":"Yasuyuki Shigematsu, Rumiko Saito, Gulanbar Amori, Hiroaki Kanda, Yu Takahashi, Kengo Takeuchi, Shunji Takahashi, Kentaro Inamura","doi":"10.1111/cas.16315","DOIUrl":null,"url":null,"abstract":"<p>The presence of <i>Fusobacterium nucleatum</i> is associated with an immunosuppressive tumor immune microenvironment (TIM) in primary colorectal cancer (CRC), contributing to tumor progression. Its persistence in CRC liver metastasis tissues raises questions about its role in modulating local and systemic immune responses and influencing recurrence patterns. This retrospective cohort study of 218 patients with CRC liver metastasis investigated the association of <i>F. nucleatum</i> in CRC liver metastasis tissues with systemic inflammation, TIM alterations, and the number of metastatic organs involved in recurrence. Two-step polymerase chain reaction (PCR), including digital PCR, detected <i>F. nucleatum</i> in 42% (92/218) of fresh-frozen specimens of CRC liver metastases. Compared with the <i>F. nucleatum-</i>none group, the <i>F. nucleatum-</i>high group showed higher C-reactive protein levels (0.82 vs. 0.22 mg/dL; <i>P</i><sub>trend</sub> = 0.02), lower numbers of CD8<sup>+</sup> cells (33.2 vs. 65.3 cells/mm<sup>2</sup>; <i>P</i><sub>trend</sub> = 0.04) and FOXP3<sup>+</sup> cells (11.3 vs. 21.7 cells/mm<sup>2</sup>; <i>P</i><sub>trend</sub> = 0.01) in the TIM, and a greater number of metastatic organs involved in recurrence (1.6 vs. 1.1; <i>p</i> < 0.001). The presence of <i>F. nucleatum</i> in CRC liver metastasis tissues was associated with increased systemic inflammation, TIM alterations, and a greater number of metastatic organs involved in recurrence. These findings suggest a potential contribution of <i>F. nucleatum</i> to the metastatic propensity of CRC cells and could inform future research to enhance understanding of the interaction between tumor, host, and microbes in the metastatic process.</p>","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":"115 10","pages":"3248-3255"},"PeriodicalIF":4.5000,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11447885/pdf/","citationCount":"0","resultStr":"{\"title\":\"Fusobacterium nucleatum, immune responses, and metastatic organ diversity in colorectal cancer liver metastasis\",\"authors\":\"Yasuyuki Shigematsu, Rumiko Saito, Gulanbar Amori, Hiroaki Kanda, Yu Takahashi, Kengo Takeuchi, Shunji Takahashi, Kentaro Inamura\",\"doi\":\"10.1111/cas.16315\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The presence of <i>Fusobacterium nucleatum</i> is associated with an immunosuppressive tumor immune microenvironment (TIM) in primary colorectal cancer (CRC), contributing to tumor progression. Its persistence in CRC liver metastasis tissues raises questions about its role in modulating local and systemic immune responses and influencing recurrence patterns. This retrospective cohort study of 218 patients with CRC liver metastasis investigated the association of <i>F. nucleatum</i> in CRC liver metastasis tissues with systemic inflammation, TIM alterations, and the number of metastatic organs involved in recurrence. Two-step polymerase chain reaction (PCR), including digital PCR, detected <i>F. nucleatum</i> in 42% (92/218) of fresh-frozen specimens of CRC liver metastases. Compared with the <i>F. nucleatum-</i>none group, the <i>F. nucleatum-</i>high group showed higher C-reactive protein levels (0.82 vs. 0.22 mg/dL; <i>P</i><sub>trend</sub> = 0.02), lower numbers of CD8<sup>+</sup> cells (33.2 vs. 65.3 cells/mm<sup>2</sup>; <i>P</i><sub>trend</sub> = 0.04) and FOXP3<sup>+</sup> cells (11.3 vs. 21.7 cells/mm<sup>2</sup>; <i>P</i><sub>trend</sub> = 0.01) in the TIM, and a greater number of metastatic organs involved in recurrence (1.6 vs. 1.1; <i>p</i> < 0.001). The presence of <i>F. nucleatum</i> in CRC liver metastasis tissues was associated with increased systemic inflammation, TIM alterations, and a greater number of metastatic organs involved in recurrence. These findings suggest a potential contribution of <i>F. nucleatum</i> to the metastatic propensity of CRC cells and could inform future research to enhance understanding of the interaction between tumor, host, and microbes in the metastatic process.</p>\",\"PeriodicalId\":9580,\"journal\":{\"name\":\"Cancer Science\",\"volume\":\"115 10\",\"pages\":\"3248-3255\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2024-08-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11447885/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Science\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/cas.16315\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Science","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cas.16315","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
在原发性结直肠癌(CRC)中,核分枝杆菌的存在与免疫抑制性肿瘤免疫微环境(TIM)有关,导致肿瘤进展。它在 CRC 肝转移组织中的持续存在使人们对其在调节局部和全身免疫反应以及影响复发模式方面的作用产生了疑问。这项对 218 例 CRC 肝转移患者进行的回顾性队列研究调查了 CRC 肝转移组织中的 F. nucleatum 与全身炎症、TIM 改变和复发涉及的转移器官数量的关系。包括数字 PCR 在内的两步聚合酶链反应(PCR)在 42% (92/218)的 CRC 肝转移灶新鲜冷冻标本中检测到了 F. nucleatum。与无F.nucleatum组相比,F.nucleatum高发组的C反应蛋白水平更高(0.82 vs. 0.22 mg/dL;Ptrend = 0.02),CD8+细胞数量更少(33.2 vs. 65.3 cells/mm2;Ptrend = 0.05),CD8+细胞数量更多。65.3 cells/mm2; Ptrend = 0.04)和 FOXP3+ cells(11.3 vs. 21.7 cells/mm2; Ptrend = 0.01),复发涉及的转移器官数量更多(1.6 vs. 1.1; Ptrend = 0.01)。
Fusobacterium nucleatum, immune responses, and metastatic organ diversity in colorectal cancer liver metastasis
The presence of Fusobacterium nucleatum is associated with an immunosuppressive tumor immune microenvironment (TIM) in primary colorectal cancer (CRC), contributing to tumor progression. Its persistence in CRC liver metastasis tissues raises questions about its role in modulating local and systemic immune responses and influencing recurrence patterns. This retrospective cohort study of 218 patients with CRC liver metastasis investigated the association of F. nucleatum in CRC liver metastasis tissues with systemic inflammation, TIM alterations, and the number of metastatic organs involved in recurrence. Two-step polymerase chain reaction (PCR), including digital PCR, detected F. nucleatum in 42% (92/218) of fresh-frozen specimens of CRC liver metastases. Compared with the F. nucleatum-none group, the F. nucleatum-high group showed higher C-reactive protein levels (0.82 vs. 0.22 mg/dL; Ptrend = 0.02), lower numbers of CD8+ cells (33.2 vs. 65.3 cells/mm2; Ptrend = 0.04) and FOXP3+ cells (11.3 vs. 21.7 cells/mm2; Ptrend = 0.01) in the TIM, and a greater number of metastatic organs involved in recurrence (1.6 vs. 1.1; p < 0.001). The presence of F. nucleatum in CRC liver metastasis tissues was associated with increased systemic inflammation, TIM alterations, and a greater number of metastatic organs involved in recurrence. These findings suggest a potential contribution of F. nucleatum to the metastatic propensity of CRC cells and could inform future research to enhance understanding of the interaction between tumor, host, and microbes in the metastatic process.
期刊介绍:
Cancer Science (formerly Japanese Journal of Cancer Research) is a monthly publication of the Japanese Cancer Association. First published in 1907, the Journal continues to publish original articles, editorials, and letters to the editor, describing original research in the fields of basic, translational and clinical cancer research. The Journal also accepts reports and case reports.
Cancer Science aims to present highly significant and timely findings that have a significant clinical impact on oncologists or that may alter the disease concept of a tumor. The Journal will not publish case reports that describe a rare tumor or condition without new findings to be added to previous reports; combination of different tumors without new suggestive findings for oncological research; remarkable effect of already known treatments without suggestive data to explain the exceptional result. Review articles may also be published.